


# \*New Aspects In Molecular Biology Of Keratoacanthoma {KA}\*

## Would It Help In Distinguishing Between KA & SCC ?

### Introduction

- Keratoacanthomas (KA) are common but exceptional benign tumors, often appearing on sun-exposed areas of light skinned people and showing spontaneous resolution.
- Relying on recent results, KA is assumed to be an individual lesion with a unique molecular signature caused by alterations in the TGF- $\beta$  signaling pathway.
- These recent findings will help to understand the nature of KA and to develop new reliable diagnostic tools, simplifying the discrimination of the histologically similar KA and SCC.



### Solitary KA

- **Typical solitary KA:** is rapidly growing up to 2 cm, appearing as a rose nodule with a keratotic centre.
- **Giant KA:** usually grow larger than 2 cm, predominantly appears on eyelids and nose.
- **Subungual KA:** a rare variant which appears under nails. show rarely spontaneous regression and may destroy the terminal phalanx.
- **Mucosal KA:** extremely rare variant, which has no tendency to regress and is observed mostly intra-orally. Since intraoral mucous membranes bear no hair follicles it was suggested that these variant of KA may arise from ectopic sebaceous glands.
- **Keratoacanthoma Centrifugum:** is a rare exo-endophytic type, characterized by multi-follicular origin, progressive peripheral expansion (2-40 cm) and atrophic central healing.



### Multiple KA

- **Ferguson Smith type (MSSE):**
  - This autosomal dominant genodermatosis is characterized by sudden appearance and rapid growth, slow regression and periodical recurrence.
  - 11 mono-allelic mutations in transforming growth factor beta receptor 1 (TGF- $\beta$ 1) were identified in this phenotype.




- **KA in Muir-Torre syndrome:**
  - An autosomal dominant genodermatosis which combines visceral malignancy, notably colon cancer with sebaceous neoplasms
  - The syndrome is caused by germline mutations of hMSH2 and hMLH1 genes



- **KA with xeroderma pigmentosum:**
  - Xeroderma pigmentosum is an autosomal recessive disorder caused by defects in genes coding for DNA repair enzymes.
  - Compared to normal cells, cells of XP patients fail to repair UV-induced DNA lesions. This failure of the repair system causes development of melanoma, basal cell carcinoma, SCC and KA.



- **Reactive KA:**
  - **This type of KA** is induced by treatment of melanoma patients with the BRAF kinase inhibitors.
  - The iatrogenic tumor formation usually occurs 8 weeks after inhibitor therapy initiation by paradoxical activation of the ERK MAP kinase pathway



### Molecular biology of KA versus SCC

#### 1) TGF- $\beta$ signalling in KA and SCC:

- The implication of TGF- $\beta$  signaling in KA formation was demonstrated recently by *Goudie et al.* They ascertain a clear correlation between loss of function mutations in the TGF- $\beta$ 1 gene and a MSSE phenotype of KA.
- In total, 11 mono-allelic mutations in 18 families have been described, occurring in the cytoplasmic kinase domain or in the extracellular ligand-binding domain.
- The paradoxical role of TGF- $\beta$  signalling could explain the rapid evolution and involution of KA after ablation of TGF- $\beta$  mediated signal transduction.
- On the other hand, rather than TGF- $\beta$ 1 mutations, recently identified NOTCH1/2 receptor mutations are considered as early gatekeeper mutations in SCC development.

#### 2) Par3 signalling in KA formation:

- The Par3 pathway is implicated in KA formation and affects downstream targets of TGF $\beta$ R1 such as PI3K/Akt and MAPK.
- Specifically, Par3 is involved in apico-basal cell polarity and asymmetric cell division.

#### 3) RAF inhibitors favors KA and SCC development:

- Ninety per cent of all BRAF mutations are V600E changes, causing a higher BRAF activity thereby activating MAPK signalling pathway independently of RAS.
- A side effect of the mutation-specific BRAF V600E drug Vemurafenib in melanoma patients is the appearance of SCC or KA in 15-20% of the patients.
- While melanoma patients treated with Sorafenib also developed SCC or KA lesions in up to 7% of the cases.

### Genetics background

- Array comparative genomic hybridization (array CGH) allows the discrimination of KA and SCC in 85% of the cases.
- Recurrent aberrations on chromosome 7, 8 and 10 have been the best predictors for SCC, suggesting a role in prevention of apoptosis or activation of proliferation and infiltration for genes located in these areas.
- In contrast chromosomes 17, 19, 20 and X seemed to be aberrant mainly in KA, indicating crucial genes for KA development.

### Conclusion

- The etiology of KA involves many different factors, of which giving rise to a broad spectrum of KA variants.
- Genetic predisposition or spontaneous formation adds another level to the complex classification system of KA.
- Today, it has been concluded that SCC and the benign neoplasm KA are two distinct entities, prototypically evidenced by alterations in the TGF- $\beta$  pathway in Ferguson Smith Disease, chromosomal aberration differences and pronounced alterations in gene expression.
- Up till now, it is a difficult task to distinguish KA and SCC on histopathological grounds. Consequently, it is essential to find morphological, biological and/or molecular markers which are showing reliable differences between these two lesions to prove that a given KA is not a SCC.
- Recently published data lead us to assume that KA is distinct from SCC and caused by early gatekeeper alterations in the TGF- $\beta$  pathway.

### References

- 1-Gleich, Tobias, et al. "Keratoacanthoma: a distinct entity?." *Experimental dermatology* 25.2 (2016): 85-91.
- 2-Kwiek, Bartłomiej, and Robert A. Schwartz. "Keratoacanthoma (KA): an update and review." *Journal of the American Academy of Dermatology* 74.6 (2016): 1220-1233.
- 3-Takai, Toshihiro. "Advances in histopathological diagnosis of keratoacanthoma." *The Journal of dermatology* 44.3 (2017): 304-314.

### Presented by

**Amal Mostafa Sayed**

\*B.D.S (Cairo University )

\*Master's Candidate At Oral Pathology Department  
Faculty Of Dentistry, Cairo University

\*Demonstrator At Oral Pathology Department  
Faculty Of Dentistry, Egyptian Russian University (ERU)